Guerbet (GRBT)

Currency in EUR
9.85
+0.19(+1.97%)
Closed·
Earnings results expected in 6 days
GRBT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.379.85
52 wk Range
8.0123.70
Key Statistics
Prev. Close
9.66
Open
9.54
Day's Range
9.37-9.85
52 wk Range
8.01-23.7
Volume
19.32K
Average Volume (3m)
16.1K
1-Year Change
-50.0517%
Book Value / Share
21.19
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GRBT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.68
Upside
+18.53%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Guerbet News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid. The company also provides OptiStar Elite, a dual head contrast delivery system with an ultrasonic motor; Ready-Box, a contrast media warmer; MRI accessories and consumables for diagnostic imaging; OptiProtect 3S, a suite of services and support solution; Conray/Cysto-Conray, an iothalamate meglumine injection contrast agent for CT; Micropaque/Microtrast, a barium sulfate contrast agent for CT; Optiray, an ioversol contrast agent for CT and Cath lab; Telebrix Gastro, a meglumine ioxitalamate contrast agent for CT; and Xenetix/ScanBag by Xenetix, an Iobitridol contrast agent for CT and Cath lab. In addition, it offers OptiBolus, which allows for a uniform vascular enhancement throughout the procedure; OptiOne, a single head injector; OptiVantage Multi-use, an optimal power injector for X-ray procedures; OptiVantage, a dual-head CT contrast delivery injector; Illumena Néo, a multi-mode contrast delivery injector; Lipiodol Ultra Fluid, an iodinated ethyl ester of fatty acids of poppy seed oil; Qitexio, a range of lipiodol resistant medical devices consisting of medical syringes and a stopcock; Lipiodol Ultra Fluid for use in interventional radiology and women’s health; and Patent Blue V, a pharmaceutical drug for breast cancer. The company was founded in 1901 and is headquartered in Villepinte, France.

Employees
2700
Market
France

Compare GRBT to Peers and Sector

Metrics to compare
GRBT
Peers
Sector
Relationship
P/E Ratio
−1.1x22.1x−0.5x
PEG Ratio
0.00−0.080.00
Price/Book
0.5x2.2x2.6x
Price / LTM Sales
0.2x2.8x3.2x
Upside (Analyst Target)
23.7%31.6%45.6%
Fair Value Upside
Unlock13.9%5.3%Unlock

Analyst Ratings

0 Buy
2 Hold
2 Sell
Ratings:
4 analysts
Overall Consensus
Sell

Analysts 12-Month Price Target:

Average 11.68
(+18.53% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Mar 11, 2026
EPS / Forecast
-8.75 / --
Revenue / Forecast
200M / 220.6M
EPS Revisions
Last 90 days

GRBT Income Statement

People Also Watch

8.695
MAUP
-9.47%
20.26
EDEN
+1.86%
104.70
ABVX
+1.45%
27.88
CBLP
+3.41%
121.00
VU
+1.00%

FAQ

What Is the Guerbet (GRBT) Stock Price Today?

The Guerbet stock price today is 9.85 EUR.

What Stock Exchange Does Guerbet Trade On?

Guerbet is listed and trades on the Paris Stock Exchange.

What Is the Stock Symbol for Guerbet?

The stock symbol for Guerbet is "GRBT."

What Is the Guerbet Market Cap?

As of today, Guerbet market cap is 123.38M EUR.

What Is Guerbet's Earnings Per Share (TTM)?

The Guerbet EPS (TTM) is -8.59.

When Is the Next Guerbet Earnings Date?

Guerbet will release its next earnings report on Apr 23, 2026.

From a Technical Analysis Perspective, Is GRBT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Guerbet Stock Split?

Guerbet has split 5 times.

How Many Employees Does Guerbet Have?

Guerbet has 2700 employees.

What is the current trading status of Guerbet (GRBT)?

As of Apr 17, 2026, Guerbet (GRBT) is trading at a price of 9.85 EUR, with a previous close of 9.66 EUR. The stock has fluctuated within a day range of 9.37 EUR to 9.85 EUR, while its 52-week range spans from 8.01 EUR to 23.70 EUR.

What Is Guerbet (GRBT) Price Target According to Analysts?

The average 12-month price target for Guerbet is 11.68 EUR, with a high estimate of 13.8 EUR and a low estimate of 9 EUR. 0 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Sell. The stock has an +18.53% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.